Quantcast

Latest advanced prostate cancer Stories

2008-12-24 16:52:00

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still...

2008-10-07 09:00:56

Bavarian Nordic, an industrial biotechnology company, has evaluated the mature Phase II data from the therapeutic prostate cancer vaccine candidate Prostvac that had been obtained as part of the recently entered partnership with the National Cancer Institute in the US. The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after four years of follow-up show that patients receiving Prostvac had a statistically significantly...

2008-10-07 09:00:14

MOUNTAIN VIEW, California, October 7 /PRNewswire/ -- BN ImmunoTherapeutics has now evaluated the mature Phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US. The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after 4 years of follow-up show that patients receiving...

2008-10-07 03:00:08

KVISTGÃӚƒÃ“šÃƒ“š...RD, Denmark, October 7 /PRNewswire-FirstCall/ -- - 125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows Statistically Significant Improved Overall Survival Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate...

2008-09-22 15:00:14

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population....

2008-09-16 12:00:10

GTx, Inc. (Nasdaq: GTXI) today presented a safety analysis demonstrating that fewer men treated with toremifene 80 mg had PSA progression over time compared to placebo in the Phase III clinical trial evaluating toremifene 80 mg for the treatment of multiple serious side effects of androgen deprivation therapy (ADT) for advanced prostate cancer. These data, as well as an additional analysis of bone turnover markers and fracture risk, were presented at the 2008 Annual Meeting of the American...

2008-08-19 09:00:17

The Prostate Cancer Foundation (PCF) today announced 19 Young Investigators Awards for 2008. Designed to encourage the most innovative research thinkers to continue their careers in prostate cancer research, the awards provide recipients with $75,000 annually for three years to support specified research programs. These awards, totaling $225,000 each, are matched by the recipients' institutions. This round of Young Investigator Awards represents a new $4.3 million commitment by the PCF to the...

2005-08-26 11:28:14

NEW YORK (Reuters Health) - Among middle-aged and older men, those who have had PSA tests are less likely to be found to have prostate cancer that has spread to other sites in the body, Canadian researchers report. Dr. Jacek A. Kopec told Reuters Health, "There was a 35 percent reduction in risk among those who were screened." Further, he added, "We observed a reduction in risk for both men under 60 years of age and those 60 years or greater, although the effect appears to be...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related